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What is damaging the kidney in lupus nephritis?
Anne Davidson, MBBS
Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 
Manhasset, New York, NY 11030*
Summary
Despite marked improvements in the survival of patients with severe lupus nephritis over the last 
50 years the rate of complete clinical remission following immune suppression is less than 50% 
and renal impairment still occurs in 40% of affected patients. An appreciation of factors leading to 
the development of chronic kidney disease (CKD) following acute or subacute renal injury in 
lupus patients is beginning to emerge. Processes that contribute to endstage renal injury include 
continuing inflammation, activation of intrinsic renal cells, cell stress and hypoxia, metabolic 
abnormalities, aberrant tissue repair and tissue fibrosis. This understanding is leading to the 
development of novel or adjunctive therapies that may protect from the secondary non-immune 
consequences of acute injury. Approaches based on a molecular/proteomic/lipidomic classification 
of disease should yield new information about the functional basis of disease heterogeneity so that 
the most effective and least toxic treatment regimens can be formulated for individual patients.
Introduction
Lupus nephritis (LN) affects 30–60% of adults and up to 70% of children with systemic 
lupus erythematosus (SLE) and is characterized by the glomerular deposition of immune 
complexes followed by recruitment of an inflammatory response. Glomerular disease is 
classified by light microscopy into five histologic subtypes of which classes III–V have the 
potential for long term damage. Further histologic classification uses composite scores for 
active inflammation and chronic scarring (1–5). Although classification drives therapeutic 
decision-making, the current scheme does not adequately predict which patients will 
respond to therapy (3, 6–7), indicating that additional phenotyping based on mechanisms of 
tissue injury is required. In addition, patients in clinical remission may exhibit progressive 
inflammation and fibrosis in repeat biopsies suggesting that improved disease monitoring 
could prevent undertreatment of subclinical disease (8–9).
While advances in immunosuppressive regimens and general medical care have erased most 
of the differences in long-term outcomes between proliferative and membranous LN (7, 10–
11), the rate of complete remission for proliferative disease remains below 50% (12–14), and 
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up to 40% of LN patients still develop some degree of renal impairment (11, 14). This 
failure of immunosuppressive agents to adequately treat LN, even in the setting of well-
monitored clinical trials, reflects an incomplete understanding of disease pathogenesis. 
Either immune cell proliferation is not the only relevant cause of renal injury, or there is a 
therapeutic time window after which this type of intervention is no longer effective.
In the first section of this review I will discuss current knowledge of LN pathogenesis 
including disease initiation by immune complexes, immune activation in the kidney, and the 
responses of renal parenchymal cells to this insult. In the second part I will discuss 
approaches to identifying new pathogenic mechanisms, and review alternate ways to classify 
and monitor disease that include molecular and proteomic analyses. Finally I will address 
how these concepts may lead to improved therapies.
Mechanisms of renal damage
Initiation of inflammation by immune complexes
LN is initiated in most cases by the glomerular deposition of IgG and complement. Rarely, 
LN occurs in the absence of immune complexes, presumably due to direct damage by 
soluble inflammatory mediators (15). Sources of immune complexes include circulating 
anti-nuclear, anti-C1q, and crossreactive anti-glomerular autoantibodies (16–20), opsonized 
apoptotic particles, microparticles, and neutrophil NETs (21–22). Particulate DNA such as 
that within neutrophil NETs can be resistant to digestion by DNAse (22), and 
downregulation of renal DNAse I can be a late feature of disease (23). Although antibodies 
eluted from LN kidneys are enriched for anti-DNA activity, not all anti-DNA antibodies are 
pathogenic. Furthermore, non-DNA binding antibodies, some arising in situ, also contribute 
to renal disease (24–25). This heterogeneity of renal depositing antibodies limits the ability 
of serum antibody profiles to predict LN flares (26).
Immune complexes initiate renal damage by several mechanisms (Figure 1). Complexes that 
deposit in the subendothelium injure endothelial cells and are the hallmark of Class III and 
IV proliferative disease. These deposits have access to the vascular space and may activate 
circulating myeloid cells that express Fc receptors, allowing them to infiltrate the renal 
tissue (27). By contrast, subepithelial deposits, found in Class V disease, injure podocytes 
but elicit a less severe inflammatory response as they contact only the urinary space. If the 
glomerular basement membrane ruptures however, these immune complexes can access the 
whole glomerulus. Immune deposits may initiate the complement cascade, or they may 
directly activate intrinsic glomerular cells (28–29), inducing the release of inflammatory 
chemokines and cytokines. Complexes containing nucleic acids additionally activate 
intracellular TLRs, thereby enhancing the inflammatory response.
Immune mechanisms of tissue injury
Soluble inflammatory mediators—Following immune complex deposition, a large 
variety of inflammatory mediators is produced in LN kidneys with spreading of the response 
as disease progresses (28, 30). Several locally produced cytokines and chemokines that 
contribute to inflammatory damage and whose absence or inhibition greatly attenuates 
disease activity have been identified. Examples include CCL2, a chemokine expressed early 
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in the glomerulonephritis process, and TNF that is expressed at proteinuria onset (31–32). A 
Type I IFN signature is also a feature of LN kidneys (33–34). IFN has multiple detrimental 
effects on the kidneys including vascular rarefaction and injury to glomerular parietal cells 
and podocytes (35–36). Once tissue injury occurs, soluble products released from injured 
cells amplify the inflammatory response by stimulating extracellular and intracellular innate 
immune receptors (37–41). Podocytes, for example, are sensitive to TLR-mediated signals 
and other inflammatory mediators such as NO, which induce foot process effacement and 
podocyte loss (42). Nevertheless, not all renal inflammatory mediators are necessary for the 
inflammatory process. For example, IL-17 deficiency alters the course of LN only in some 
models in which TH17 cells infiltrate the kidneys (43–44). Thus, targeting of single 
inflammatory mediators may not be sufficient to reverse the established renal inflammatory 
response that becomes more complex over time.
Cellular infiltrates—Inflammatory cells may infiltrate the kidney through glomerular or 
interstitial blood vessels. The anatomic organization of these infiltrates is quite variable. 
They may consist of scattered cells, disorganized aggregates, or rarely, organized structures 
containing germinal centers (45). There is also evidence for in situ activation of pathogenic 
adaptive immune responses to degraded or modified renal antigens. Both B cells and T cells 
from LN kidneys are clonally expanded, and the same T cell expansions have been detected 
in the peripheral blood (46–47). Multiple T cell cytokines such as IFNγ, IL-21 and IL-17 
have also been detected in LN kidneys (48), and T cells appear in the urine of LN patients 
(49). In a small exploratory study, clonal CD8 T cell infiltrates were found adjacent to 
epithelial cells in LN biopsies and were associated with more severe disease, suggesting an 
effector function elicited by local antigens (47).
Strikingly, a measurable proportion of B cells derived from human LN biopsies recognize 
vimentin, an intracellular structural protein that is cleaved and extruded from apoptotic cells 
(46). Serum anti-vimentin antibodies are associated with decreasing GFR and increasing 
tubulointerstitial damage in other forms of CKD, and are similarly associated with severe 
interstitial disease in LN (46, 50). Autoantibodies to annexin1 and αenolase have also been 
detected in LN kidneys (51). These local adaptive immune responses may amplify 
inflammation independently of systemic autoimmunity.
Macrophages play a central role in both injury and repair; renal infiltration of LN kidneys 
with macrophages, particularly at the second biopsy, is associated with poor prognosis (52–
54). Both infiltrating inflammatory macrophages and resident interstitial macrophages may 
be present in diseased kidneys (53, 55–56). Macrophages recruited from the peripheral blood 
are pro-inflammatory during acute inflammation but can then switch to a reparative 
phenotype (53, 57). Resident interstitial macrophages may have self-renewal properties (58), 
and in mouse models of chronic LN, they increase in number, become activated, and acquire 
MMP and cathepsin activity, suggesting that they contribute to aberrant tissue remodeling 
(30, 55).
It is increasingly recognized that several types of dendritic cells also infiltrate the kidneys 
during LN (59) potentially propagating local adaptive immune responses (60). Importantly, 
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an increase in both CD141hi and myeloid DCs is observed in human glomerulonephritis 
biopsies and correlates with fibrosis (61).
Non-immune mechanisms of tissue injury in LN
Several lines of evidence suggest that non-immune mechanisms of renal damage need to be 
therapeutically addressed in LN. First, many patients do not adequately respond to 
immunologic interventions. Second, remission can take months, during which time damage 
may continue to accrue. Third, progression may occur even if systemic autoimmunity is 
controlled. Although the role of each intrinsic renal cell during the stages of injury and 
repair is still not fully understood, some general mechanisms of CKD should also be 
applicable to LN (Figure 2).
Disruption of cell-cell interactions—Maintenance of the complex structure of the 
nephron requires cell-cell interactions (62) (Figure 1). In the glomerulus, endothelial cells 
directly contact mesangial cells (63). Mesangial cells sequester latent TGFβ, preventing 
TGFβ-mediated damage to endothelial cells (64). Endothelial cells produce PDGF-B whose 
interaction with PDGF-Rβ on mesangial cells is required for glomerular development. 
Expression of PDGF isoforms is upregulated in many forms of renal injury, causing 
mesangial hyperproliferation, matrix production, cytokine and chemokine release, and renal 
fibrosis (65).
Podocytes and endothelial cells also interact by bidirectional diffusion of cytokines/growth 
factors through the glomerular basement membrane (63). Podocytes secrete angiopoietin 1 
and VEGF-A that support endothelial cell survival; loss of renal VEGF-A characterizes LN 
both in humans and mouse models and distinguishes LN from other forms of CKD (34). In 
diseased tissue, both activated glomerular endothelial cells and damaged podocytes release 
endothelin 1 that amplifies glomerular injury by causing mitochondrial stress (66). Since 
podocyte regenerative capacity is limited in adults, loss of podocytes eventually leads to 
glomerulosclerosis. As nephrons are lost, compensatory mechanisms cause a rise in 
intraglomerular pressure and glomerular stress in the remaining nephrons (67).
A cell that has received much recent attention is the pericyte which contacts and shares a 
basement membrane with capillary endothelial cells. Pericytes secrete VEGF-A, chemokines 
and other inflammatory mediators, they help maintain endothelial cell quiescence, they 
contribute to the basement membrane and they regulate both medullary blood flow and cell 
traffic through the endothelial barrier during inflammation (68–70). Mesangial cells are the 
pericytes of the glomerulus and the interstitium has its own pericyte network attached to 
tubular capillaries. During inflammation, these pericytes rapidly dissociate from tubular 
capillaries and migrate into the interstitial space where they differentiate into myofibrobasts 
(71).
Abnormal vascular function and tissue hypoxia—Glomerular endothelial cells are 
coated with a glycocalyx layer that forms a crucial barrier to protein loss (72); this barrier 
can be degraded by the enzyme heparanase that is induced by endothelial hypoxic stress 
(73). As pericytes dissociate from capillaries and VEGF-A production diminishes, the 
capacity for angiogenesis and capillary repair is lost, leading to capillary rarefaction in both 
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the glomerulus and the interstitium (71, 74). Other disturbances of angiogenesis reported in 
LN include a decrease in the ratio of pro-angiogenic Ang1/anti-angiogenic Ang2, 
downregulation of the angiogenic factor FGF-2, an increase in the VEGF inhibitor 
ADAMTS-1, and alterations in endothelial nitric oxide synthase (68, 75–77). In a mouse 
model of LN, downregulation of VEGF-A and FGF-2 persists even after induction of 
complete remission, suggesting that vascular injury is not completely reversible (30).
Some areas of the kidney, especially the medulla, maintain a low pO2 even under normal 
physiologic conditions and are sensitive to hypoxia. The interstitial blood supply derives 
from post-glomerular blood vessels, so glomerular hypertension and sclerosis can cause 
interstitial ischemia. Loss of VEGF-A, oxidative stress due to inflammation, increased 
energy demands, endothelial cell injury by cytokines, enhanced endothelin release, 
hypertension and anemia may all contribute to hypoxia (78–80); the relative contribution of 
each of these mechanisms is not well understood.
Tubular dysfunction and atrophy—Ischemia, hypertension or failed regeneration 
contribute to atrophy of tubular epithelial cells; such injury promotes both interstitial 
immune cell infiltrates and fibrosis. Recent studies have shown that injured renal tubular 
cells have a defect in fatty acid oxidation which causes mitochondrial dysfunction, 
reprograms them to a pro-fibrotic phenotype, and contributes to their death (30). The defect 
can be reversed by tubule-specific expression of the mitochondrial biogenesis regulator 
PGC-1α. Importantly, human fibrotic kidneys have a similar alteration in tubular fatty acid 
metabolism, suggesting a potential new therapeutic approach (81–82).
Renal fibrosis and progression to chronic kidney disease—Renal fibrosis is a 
poor prognostic feature in LN as in CKD generally. The extent of fibrosis is determined by 
the balance of matrix production with enzyme-mediated matrix breakdown and turnover 
(83). Mesangial cells are the classical myofibroblasts in the glomerulus, but parietal 
epithelial cells and podocytes may also contribute (83). In the interstitium, pericytes and 
resident fibroblasts are the major sources of myofibroblasts that produce extracellular 
matrix, MMP inhibitors and collagen (84). Both tissue macrophages and tubular epithelial 
cells produce growth factors that support myofibroblast differentiation, including TGFβ, 
PDGF and CTGF (85–86). These factors are balanced by local anti-fibrotic factors such as 
the TGFβ antagonists BMP-7 and hepatocyte growth factor. In addition, cytokines, 
chemokines, matrix proteins, procoagulants and remodeling enzymes produced by 
inflammatory cells, tubular cells and macrophages provide a pro-fibrotic microenvironment 
(87).
Although it has not been shown unequivocally that an area of fibrosis will damage adjacent 
healthy nephrons (88), several lines of evidence indicate that fibrosis can amplify renal 
damage. Fibroblasts may contribute to tissue injury by producing pro-inflammatory 
mediators (89). Fibrotic tissue may disrupt normal anatomic structures and interfere with 
oxygen diffusion, thus exacerbating hypoxia (83). In addition, epigenetic changes can 
reprogram fibroblasts to maintain their profibrotic state even after inflammation has resolved 
(90–92). One epigenetic change that has received considerable attention is the upregulation 
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of miR-21 that protects against acute renal inflammation and damage but may also 
exacerbate fibrosis (93–94).
Identifying novel pathways that contribute to initiation and progression of 
lupus nephritis
Improved therapy for SLE will likely require disease classification based on pathogenic 
mechanisms. Some of these mechanisms will be common to most patients, some may be 
stage-specific, and others may apply to smaller patient subgroups or even individuals. 
Several approaches to identify commonly shared pathways have been explored.
Clinical and Epidemiologic studies
Factors associated with poor outcomes in lupus nephritis are shown in Table 1 (11, 95–96). 
Long term outcome depends on the degree of treatment response, with resolution of 
proteinuria being the best surrogate marker of a favourable prognosis (97–98). The severity 
of renal damage at presentation, manifested by serum creatinine and the degree of interstitial 
inflammation and fibrosis, strongly influences the response to treatment. These data support 
the need for improved monitoring of high risk individuals, and suggest that early detection 
of LN and prompt intervention will improve outcomes. Not surprisingly, non-response to 
therapy, recurrent flares and residual inflammation or fibrosis at repeat biopsy are associated 
with a poorer prognosis (54, 99–100). Repeat biopsies are not routinely performed but may 
be useful to guide tapering regimens and/or the need for changes in maintenance therapies.
Importantly, recent epidemiologic data from the US has shown an increase in ESRD in 
uninsured individuals and in geographic areas with poor access to ambulatory care, 
indicating a significant effect of healthcare policy, healthcare access and patient compliance 
on LN outcomes (101). Similar results have been shown in other countries (102). Unless this 
public health issue is addressed it is difficult to envision improved outcomes by medical 
management alone.
Genetic risk for LN
Genome-wide analyses (GWAS)—A recent meta-analysis of 3 GWAS identified 
several inherited polymorphisms that predispose to initiation of LN, including the PDGFRA 
locus, the glucose transporter Slc5A11, and hyaluronan synthase 2 that is involved in 
extracellular matrix formation (103). Other risk genes include ABIN1, TNFSF4, Stat4, 
ITGAM, kallikreins and FcγRIIIa low-binding alleles (104–110). These results suggest a 
link between inflammation and LN as well as a contribution from pathways that regulate the 
renal response to inflammation and injury. However the relative risk associated with most of 
these genetic variants is low, and some are relevant only in certain ethnic populations, 
making it challenging to generate a clinically meaningful genetic risk-prediction test. The 
function of the various polymorphisms will need to be unravelled in order to understand 
their clinical significance.
Only a few small studies have addressed the genetic risk for increased disease severity in LN 
patients. Polymorphisms in APOL1 and MYH9 confer an increased risk of renal failure in 
Davidson Page 6
Nat Rev Rheumatol. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
other chronic renal diseases, and appear to confer a modest risk for LN progression that may 
be dependent on ethnicity (111–113). No studies have addressed the genetic basis for 
responsiveness to therapy.
Local epigenetic changes—The epigenetic landscape of renal injury is just starting to 
be described, particularly in the interstitium (114–115). Examples relevant to LN include 
chromatin structure modifications that regulate the production of CCL2 and TNF, DNA 
demethylation that regulates C3 production and histone acetylation that regulates the 
production of PDGF and pro-fibrotic genes (115). Histone deacetylase inhibitors alleviate 
progression in multiple models of renal injury and fibrosis by preventing cytokine release 
and cell apoptosis and by inducing the protective molecule BMP-7 (116–117). Epigenetic 
changes can also be mediated by non-coding RNAs. TGFβ induces several miRNAs that 
enhance pro-fibrotic genes while at the same time inhibiting miRNAs that are protective 
(93–94). The utility of blood and urine miRNA signatures as biomarkers for LN is starting to 
be examined (118–119).
Molecular and proteomic signatures of renal disease
Molecular and/or proteomic phenotyping of the kidney or urine may identify the 
immunologic and/or injury process currently affecting each individual, and could deliver 
biomarkers to improve patient stratification for clinical trials and a more rational therapeutic 
approach.
Molecular profiling of LN kidneys—Several studies have shown signatures of immune 
cell infiltration and activation, extracellular matrix formation and fibrosis, endothelial cell 
activation, fibrinolysis, mitochondrial dysfunction, and tubular injury (34, 120–121). 
Because pre-nephritis and repeat biopsies are rarely available from humans, mouse models 
have been useful for characterizing renal molecular profiles at sequential disease stages. 
Overlay of these data onto data from human LN biopsies allows identification of pathways 
that are relevant to human disease. Using this approach in NZB/W lupus-prone mice we 
identified two dominant gene clusters that are dynamically regulated during disease 
progression; the first is detected at proteinuria onset and reflects the inflammatory 
component of nephritis – the second occurs during established proteinuria and reflects the 
mitochondrial and metabolic signature of chronic disease. Remission induction therapy 
administered promptly after nephritis onset reverses most of this abnormal gene expression 
profile but we noted that the mitochondrial and metabolic signature recurred before clinical 
relapse, perhaps reflecting an increased propensity to tissue hypoxia conferred by the initial 
tissue insult (30). By following mice from remission to relapse, we further identified 
podocyte loss, renal tubular dysfunction, endothelial cell activation and tissue remodeling as 
the functional features associated with the progression to renal failure (30). Some of these 
processes may be resistant to standard immune suppression (34, 122).
One important observation in mice is that glomerular disease does not always progress to 
tubular and endothelial dysfunction (123–124). For example, BAFF deficient or BAFF-R-Ig 
treated lupus-prone mice have autoantibodies, glomerulonephritis and interstitial 
inflammatory infiltrates but do not die of renal failure (30, 123). Similarly, a genetic model 
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has been generated in which acute glomerular injury occurs, but progression to CKD does 
not (125). How this transition from renal inflammation to renal failure is regulated is not 
completely understood (126–128) and is an important knowledge gap that needs to be filled 
(121–123). In addition, there are several LN models in which renal deposition of immune 
complexes does not induce the recruitment of effector cells. These include myeloid cell 
deficiency of Fc receptors, CCL2 deficiency and intense costimulatory blockade (27, 129–
130). These studies, in sum, suggest that there are several opportunities for therapeutic 
intervention that target the effector response in the kidney, regardless of systemic 
autoimmunity.
A problem with the interpretation of molecular profiles of whole tissues is that the signatures 
are biased towards the most frequent cell types and towards infiltrating cells that are rare in 
normal kidneys. The only way to overcome these biases is to study each cell type 
individually. No studies of this type have as yet been performed in human LN biopsies and 
even the data from mouse models is still quite limited. Molecular studies in both mice and 
humans have suggested that macrophages/DCs are key players in the development of LN 
(34). Comparative molecular profiling of isolated renal macrophages from young and 
nephritic NZB/W mice and NZW/BXSB mice (34, 55) revealed that several functional 
pathways are upregulated in nephritic macrophages including the alternate complement 
pathway, cell adhesion, phagocytosis and efferocytosis, Fc receptor signaling, the nucleic 
acid sensing pathway and tissue repair. Pathways that are downregulated include fatty acid 
metabolism and angiogenesis. This profile suggests aberrant resolution of inflammation 
which may be driven by ongoing immune complex deposition and/or tissue damage. It 
remains to be determined whether it is possible to harness the reparative function of 
macrophages for optimal tissue repair without fibrosis.
Proteomic analysis of LN kidneys—Proteomic analysis of kidneys has been 
challenging due to the limited amount of available tissue and the inability to detect small or 
low abundance proteins; the feasibility of this approach is increasing with new technical 
advances. A proteomic analysis of human lupus glomeruli revealed loss of podocyte 
proteins, activation of the alternate complement pathway, loss of anti-oxidants and 
downregulation of normal metabolic pathways, consistent with the findings of the molecular 
studies (131–132). Analyses of proliferative LN biopsies using a targeted set of 500 immune 
response genes showed that activation of IFN pathways, production of IL-10 and T and B 
cell signaling pathways are associated with lack of response to therapy (6). These data are 
consistent with the clinical observation that interstitial infiltrates are associated with poor 
prognosis. It is also becoming clear that variability in the renal proteome can occur within a 
WHO Class, adding potential for subclassification based on proteomic analysis (133).
In sum, the preliminary molecular and proteomic studies of LN kidneys have extended 
mechanistic knowledge beyond the histologic data by identifying two phases of disease 
characterized by inflammation and metabolic dysfunction, have identified both shared and 
unique effector signatures and have identified a number of checkpoints along the path to 
irreversible renal damage that could potentially be targeted by new therapies. The molecular 
studies have been less successful at identifying the earliest features of LN since only few 
genes are upregulated in the kidneys prior to the onset of proteinuria (30); a proportion of 
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these is associated with steroid and lipid metabolism. Proteomic and metabolomic studies 
may be more suitable for detecting such early changes (134–135).
Analysis of urines—Longitudinal monitoring of urine offers a window into the kidney 
that could be used for treatment decisions. The technical challenges inherent in this 
approach have recently been reviewed (133). The major clinical use of urine proteomics has 
so far been to identify biomarkers that either predict an impending renal flare (6, 136) or 
identify response to therapy. There are several longitudinal studies of single urine 
biomarkers including the chemokine CCL2, the tubular marker lipocalin2, the acute phase 
protein hepcidin and the TNF-like molecule TWEAK (reviewed (133, 137)). These studies 
are still preliminary and have not yet been reliably reproduced or tested in the setting of a 
clinical trial. Combination panels of these and other potential biomarkers identified in cross-
sectional studies may have a higher predictive value than single analytes alone.
It is important to note that cells and microparticles of cells are also shed into the urine during 
inflammation and this could be exploited for discovery of other protein and RNA-based 
biomarkers and for early detection of podocyte loss.
Using therapeutics to test the pathogenicity of target molecules—A final 
approach to identifying key pathways in LN is to identify molecules that are potentially 
pathogenic based on their known biology and then test their role in pre-clinical models either 
by genetic depletion or therapeutic targeting. This approach is often successful when the 
correct preclinical model expressing the protein of interest is used and the treatment is timed 
either before or at the first presentation of LN (138). Nevertheless this is proving to be a 
cumbersome and expensive approach in human LN that has been hampered by the 
primitiveness of disease phenotyping, the confounding effects of standard medications such 
as glucocorticoids and the absence of a uniformly accepted definition of renal outcome 
(139).
When choosing such targets, it is important to consider the sometimes opposing effects of 
pleiotropic immune pathways and cytokines on systemic immunity vs. local effector 
responses. Genetic deficiencies of TNF, TGFβ, components of the innate pathway such as 
TLR9 and STING and Nox2, and inflammasome components NLRP3 and ASC all induce or 
exacerbate autoimmunity in mice (140–142). This may be due to the loss regulatory 
functions of these proteins or to diminished capacity to fully control infectious insults. On 
the other hand both TNF and TGF beta are highly expressed in inflamed kidneys and their 
inhibition at this stage of disease improves disease outcome in mouse models (32, 143). TNF 
inhibition does indeed improve chronic LN in patients without inducing systemic flares 
although its clinical utility has been limited by other toxicities (144). Nevertheless, targeting 
these types of pathways will need to be approached with caution.
Implications for treatment
Targeting systemic autoimmunity
Given the role of systemic autoimmunity in the initiation of LN, a major focus of 
management should be on prevention. Indeed in mouse models of lupus, LN can be 
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completely prevented by immune interventions that prevent the renal deposition of 
autoantibodies or by genetic manipulations that prevent tissue responses to immune complex 
deposition (145). There are however many obstacles to a similar approach in humans 
including the heterogeneity of immune responses in individual patients, the absence of non-
invasive monitoring tools for early detection, the potential toxicities of new therapies in 
patients with quiescent disease and the expense of time-to-flare studies that need large study 
cohorts.
Once disease onset occurs, there may only be a limited time window before disease 
mechanisms that are insensitive to preventive strategies arise. In mice it is much easier to 
prevent disease onset than to treat established disease with drugs that target T or B 
lymphocytes and in some strains drug combinations are needed to induce remission (138, 
145). Delay in diagnosis and treatment may result in the recruitment of inflammatory 
amplification circuits or the onset of metabolic or structural changes in the kidneys that are 
difficult to reverse with immunotherapy. Variability in treatment responses may also be due 
to intrinsic differences between patients. Considerable variations in responses to 
immunotherapy are observed in different mouse models of LN even when intervention is 
initiated at disease onset (138); this may reflect heterogeneity in the severity of 
inflammation, the relative involvement of innate vs. adaptive immune pathways, the balance 
of inflammation vs. metabolic abnormalities and the degree of tissue hypoxia, nephron loss 
and tubular regenerative capacity (Figure 3).
Although biologic agents have not yet been successful in patients with LN (146–147) many 
new approaches remain to be tested (146, 148). Obvious targets include key cytokines 
expressed in inflamed kidneys such as IL1, IL6, M-CSF, IFNγ, Type I IFN, BAFF, IL17 and 
IL21, signaling pathways such as tyrosine kinases, costimulatory molecules such as ICOS 
and TWEAK (149) and effector molecules such as those in the complement pathway 
(reviewed (150)). Chemokines are also appealing targets but despite extensive efforts have 
not yet successfully been translated to human autoimmune disease (151–152). One 
successful pilot approach has been to deplete plasma cells with a proteasome inhibitor, thus 
clearing immune complexes and allowing the kidney to heal (153). Nevertheless, the overall 
experience with immune suppression shows that non-immune based approaches to 
preventing disease progression (154) also need to be considered in order to optimize the 
resolution and repair process (Table 2). This field is still in its infancy but new approaches 
are being tested and developments in this field may also be applicable to LN.
Targeting endothelial cell dysfunction
An improved understanding of the mechanisms of endothelial dysfunction and hypoxia may 
lead to novel therapies. Endothelial glycocalyx deterioration may be prevented by 
angiotensin 2 inhibition and mycophenolate can inhibit PDGF-B production (155). ACE 
inhibitors also reduce endothelial activation by increasing NO production independently of 
their anti-hypertensive effects (76). Podocytes lacking both endothelin receptors are 
protected from damage in animal models of diabetes and an endothelin antagonist reduced 
proteinuria in patients with diabetic nephropathy (156). Targeting of VEGF-A (157) or 
PDGF has proved more challenging because the relationships between angiogenesis, 
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inflammation and fibrosis are still not fully understood. For example, some proangiogenic 
factors also enhance inflammation or fibrosis (76) and PDGF may be involved in tubular 
regeneration (85). In addition angiogenesis may be detrimental early in disease, helping to 
mediate glomerular hypertrophy, before becoming dysfunctional at later stages (76).
Preventing and reversing renal fibrosis
Several strategies for preventing or reversing renal fibrosis are in clinical development and 
include monoclonal antibodies to TGFβ and CTGF or their downstream signaling pathways, 
growth factor antagonists such as BMP-7 mimetics, phosphodiesterase inhibitors and 
NADPH oxidase inhibitors (85, 158). Nevertheless, the wide array of potentially profibrotic 
factors that arise in inflamed kidneys (87) suggest that broad approaches may be needed. 
One exciting new therapeutic area is the prevention of tubular epithelial injury based on a 
better understanding of the mechanisms of tubular stress. Data from mouse models suggests 
that pharmacologic enhancement of fatty acid oxidation may protect tubules from death and 
help prevent fibrosis (82).
Reparative macrophages that arise during the healing phase of acute inflammation may act 
to reverse early fibrosis by endocytosis and degradation of collagen (159) or by secreting 
enzymes that break down collagen and matrix. These macrophages can also stimulate 
tubular epithelial cell regeneration through a mechanism involving the Wnt pathway (160). 
Importantly however, prolonged exposure to reparative macrophages may cause renal 
fibrosis or excessive remodeling (161). Strategies targeting dysfunctional macrophage repair 
have included antagonism of the interstitial macrophage receptor CCR1 and of the resident 
macrophage receptor CX3CR1 (162). More effective targeting of macrophages awaits a 
better understanding of how their inflammatory, pro-fibrotic and reparative functions are 
regulated during the various stages of disease.
Conclusions
Progress continues to be made in our understanding of the mechanisms of acute and chronic 
renal injury as they pertain to LN. Although immunosuppressive agents continue to be the 
mainstay of treatment, new biologic agents continue to be tested and development of 
treatments that protect the kidneys against endothelial and tubular injury and fibrosis may 
help prevent chronic damage. Progress in developing new therapies for LN will require the 
formation of LN consortia, patient and physician engagement in research protocols, 
improved clinical trial design, improved definitions of renal outcome that may include 
second biopsies, testing of molecular and proteomic analyses in clinical trials and, finally, 
strategies for prevention and treatment based on these results. The most cost effective 
current approach involves early recognition (163) with prompt intervention and treatment of 
reversible risk factors. This requires ensuring access both to properly trained health care 
providers and to medications and is the necessary foundation upon which individualized care 
can eventually be built.
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Pubmed searches were carried out for lupus nephritis, renal fibrosis, CKD and treatment, 
AKI to CKD progression, renal interstitial inflammation, renal macrophages. In addition 
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Key points
• Lupus nephritis remains a major cause of morbidity and mortality in SLE with 
approximately 40% of affected individuals developing some degree of renal 
impairment.
• Long term prognosis is influenced by both extrinsic and intrinsic renal factors 
and depends on the severity of disease at presentation, the response to 
immunosuppressive therapy and access to high quality healthcare
• Current methods for classifying LN are based solely on light microscopy of 
kidney biopsies and do not adequately predict response to therapy or long term 
outcomes. Additional phenotyping based on mechanisms of injury may improve 
clinical decision making.
• Mechanisms of renal injury involve both local immune responses and aberrant 
responses by the renal parenchyma including disruption of cell-cell interactions 
that maintain nephron structure, loss of renal microvasculature, tubular atrophy 
and renal fibrosis. Some of these processes are not reversible with 
immunosuppressive therapy and may require different approaches based on 
targeting non-immune mechanisms for disease progression.
• Although LN is initiated by immune complex deposition, the response to injury 
in individual patients is variable and may reflect the balance of innate vs 
adaptive immunity, inflammation vs metabolic changes, the degree of hypoxia 
and the capacity for regeneration and fibrosis.
• Genetic analyses, molecular profiling and proteomic analyses are being used to 
discover mechanisms of renal injury and suggest new and more individualized 
therapeutic approaches.
• Studies in mouse models show that progression to CKD is not inevitable even if 
systemic autoimmunity persists and that several checkpoints in the progression 
pathway are susceptible to therapeutic intervention.
• Because clinical remission and renal histologic remission are not always 
correlated, improved disease monitoring and/or second biopsies may help 
identify patients at risk of progression and in need of more intense maintenance 
therapy
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Figure 1. 
Glomerular injury in LN: View of a glomerular loop containing endothelial cells (yellow) 
lined by a glycocalyx (orange), mesangial cells (ochre) and podocytes (brown). Podocytes 
are separated from endothelial cells by the glomerular basement membrane (GBM -red). The 
glomerulus is contained by Bowman’s capsule (BC) that is lined by parietal epithelial cells. 
Immune deposits (blue) may be found in the mesangium, subendothelium, or subepithelium. 
Subendothelial deposits are in contact with the vascular space (V) and can recruit myeloid 
cells (My) into the renal parenchyma. Subepithelial cells are in contact with podocytes and 
the urinary space (U). Podocytes and endothelial cells communicate with each other by 
transfer of soluble growth factors across the GBM, whereas mesangial cells and endothelial 
cells can interact directly via receptors and their ligands. Alterations of these factors in LN 
are shown by the arrows and color coded according to cell type.
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Figure 2. 
Interstitial injury in LN: A single nephron with its tubular and capillary system is shown. 
Cellular components that contribute to interstitial injury include tubular cells, endothelial 
cells (Cap), pericytes (P), fibrobasts (F), inflammatory lymphocytes (Ly), infiltrating and 
resident macrophages (Mac) and infiltrating dendritic cells (DC). Both pericytes and 
fibrobasts can differentiate into myofibroblasts (Myo). The sequential processes occurring 
during the progression to CKD are shown on the right and key molecules are shown on the 
left.
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Figure 3. 
Shared pathogenic pathways identified in the kidneys of the three different lupus-prone 
mouse strains. NZB/W and NZW/BXSB mice develop proliferative glomerulonephritis and 
NZM2410 mice develop glomerulosclerosis with limited inflammation. Pathways that are 
shared between all three strains and human LN are shown in green. The major functional 
pathway that is overrepresented in each of the three individual strains is shown in purple. 
Transcription factors are shown in blue and other pathways shared by two strains are shown 
in black. (adapted from (122))
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Table 1
Factors associated with poor prognosis in LN (7, 9, 11–12, 54, 97–98, 164)
Renal extrinsic
 Genetic
 African-American race
 Male gender
 Older age
 Socio-economic
  Delay in diagnosis
  Poor compliance
  Limited access to qualified providers
  Lack of health insurance
Renal intrinsic
 ISN/RPS histologic classes III, IV and V
 Increased serum creatinine
 Interstitial infiltrates
 Fibrosis
Mixed renal intrinsic/extrinsic
 Anemia
 Hypertension
Inadequate response to therapy
 Failure to resolve proteinuria by 6–12 months
 Recurrence
 Inflammation, macrophage infiltration, fibrosis at second biopsy
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Table 2
Potential targets of therapy in LN (76, 147, 154, 158, 162, 165)
Immune based therapies
 Innate immune mechanisms, eg inflammasome
 Adaptive immunity eg costimulatory blockade
 Effector cells, eg plasma cells, macrophages
 Effector pathways, eg alternative complement pathway, TWEAK/Fn14 pathway
 Soluble inflammatory mediators, eg cytokines/chemokines
 Signaling molecules eg, kinases, mTOR
Protection of intrinsic renal cells
 Renin angiotensin system
 Endothelin 1
 Growth factors, eg PDGF
 Oxidative stress, eg NADP oxidases
Improved microcirculation
 Phosphodiesterase 5
Anti-fibrotics
 Growth factors, eg TGFβ, CTGF
 Growth factor antagonists, eg HGF mimetic, BMP7 mimetic
Others
 Epigenomic reprogramming
 Mesenchymal stem cells
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